Atsena Therapeutics Receives FDA Designation for Treatment of Severe Congenital Eye Disease Using Gene Therapy
Atsena Therapeutics has been granted Regenerative Medicine Advanced Therapy designation from the FDA to continue their research on a cure to Leber congenital amaurosis. Patients with this disease are missing a gene that regulates retinal function and visually-guided behavior, causing blindness at an early age.
New Pest Management Hub Will Address Florida’s Buggiest Problems
The University of Florida Institute of Food and Agricultural Sciences (UF/IFAS) will create a new network focused on finding novel ways to manage bugs and pests in homes and businesses, known as the Innovation Hub for Urban Pest Management.
Entrinsic Bioscience Announces Breakthrough Innovation for Next Generation Sports and Recreational Rehydration™ Beverages
Entrinsic Bioscience has published a ground-breaking clinical study demonstrating the potential for next-generation sports and rehydration beverages, powered by its new Ultra-Hydrating HeatDefense™ formula which promotes dual action rapid rehydration with new levels of heat protection during sports, physical exertion and high heat stress.
Genascence to Present Full Data from Phase 1 Clinical Trial on GNSC-001, Company’s Lead Program in Osteoarthritis, at European Society of Gene & Cell Therapy 30th Annual Congress
Genascence Corporation, a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy using technology discovered at the University of Florida, announced that data from the Phase 1 clinical trial of GNSC-001 for the treatment of osteoarthritis (OA) demonstrated that it was safe and well tolerated.
“The Horse’s Mouth” with Enrico Levi of Inzecto
The Horse’s Mouth is a talk show where Tom McManus’s guests sidle up to his bar to discuss the intersection of sports, business, and life. Today, Tom sits with Enrico Levi of Inzecto, a UF startup licensing mosquito control technology created by Levi, Roberto Pereira, and principal investigator Philip Koehler at the UF College of Agriculture and Food Sciences.
BioMérieux Receives CE Mark for Biomarker Assay for Mild TBI
BioMérieux, which signed an agreement in 2017 with Banyan Biomarkers to commercialize its TBI assay, has obtained the CE Mark for its assay to detect two biomarkers associated with mild traumatic brain injury (mTBI).
Cannabix’s MSBS Marijuana Breathalyzer Technology Advances Quantification of THC in Breath
UF startup Cannabix Technologies Inc., developer of marijuana and alcohol breath testing devices, reported its Mass Spectrometer Breath Sampler technology along with the Breath Collection Unit have been used to quantify delta-9 THC levels from smoking and edibles in humans.
Capsida Biotherapeutics Enters Strategic Collaboration With Kate Therapeutics to Manufacture KateTx’s Next-Generation Gene Therapies
Capsida Biotherapeutics Inc. and UF startup Kate Therapeutics announced a strategic partnership to leverage Capsida's expertise and adeno-associated virus (AAV) manufacturing capabilities to enable KateTx's initial internal portfolio of muscle and heart disease programs.
NovaBone’s New Bioactive Glass Syringe for Foot & Ankle
UF startup NovaBone Products, leader in synthetic biologics, announced the Alachua, Florida, company has made commercially available a new syringe for targeted delivery of its 45S5 bioactive glass putty device for the foot and ankle market. The newly launched syringe comes in both a 2.5cc and a 5cc formulation.
Atsena Therapeutics Doses First Patient in Phase I/II Clinical Trial of ATSN-201 for Treatment of X-Linked Retinoschisis
Atsena Therapeutics announced the first patient has been dosed in its Phase I/II clinical trial, the LIGHTHOUSE study, evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS).
